About Tryptophan--tRNA ligase, mitochondrial
Tryptophan--tRNA ligase, mitochondrial (WARS2) is a protein
from Homo sapiens identified by UniProt accession
Q9UGM6, 360 residues long.
MolForge cross-references it against 0 known binders and
142 disease associations.
Target properties
| Protein name | Tryptophan--tRNA ligase, mitochondrial |
| UniProt accession | Q9UGM6 |
| Gene | WARS2 |
| Organism | Homo sapiens |
| Length | 360 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (142)
Diseases linked to this target (Open Targets).
- neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures · score 0.82
- parkinsonism-dystonia 3, childhood-onset · score 0.71
- neurodegenerative disease · score 0.56
- genetic disorder · score 0.41
- cortical surface area measurement · score 0.40
- balding measurement · score 0.37
- neuroimaging measurement · score 0.37
- mitochondrial disease · score 0.37
- brain measurement · score 0.37
- hair shape measurement · score 0.36
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UGM6-F1 | alphafold | PREDICTED | 89.75 | — |
Amino-acid sequence (360 residues)
MALHSMRKAR ERWSFIRALH KGSAAAPALQ KDSKKRVFSG IQPTGILHLG NYLGAIESWV RLQDEYDSVL YSIVDLHSIT VPQDPAVLRQ SILDMTAVLL ACGINPEKSI LFQQSQVSEH TQLSWILSCM VRLPRLQHLH QWKAKTTKQK HDGTVGLLTY PVLQAADILL YKSTHVPVGE DQVQHMELVQ DLAQGFNKKY GEFFPVPESI LTSMKKVKSL RDPSAKMSKS DPDKLATVRI TDSPEEIVQK FRKAVTDFTS EVTYDPAGRA GVSNIVAVHA AVTGLSVEEV VRRSAGMNTA RYKLAVADAV IEKFAPIKRE IEKLKLDKDH LEKVLQIGSA KAKELAYTVC QEVKKLVGFL
Explore Tryptophan--tRNA ligase, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets